TRIV-573 / Triveni Bio - LARVOL DELTA

A Study Evaluating TRIV-573 in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Triveni Bio

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth (PRNewswire) - "Proceeds from this financing will allow the company to extend the scope and rigor of clinical development of TRIV-573, including an atopic dermatitis Phase 2 clinical proof-of-concept study expected to initiate later this year."

Financing • New P2 trial • Atopic Dermatitis • Immunology

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial (PRNewswire) - "The initiation of the Phase 1 study marks rapid progress and an expansion of Triveni's clinical portfolio. The company plans to move into a Phase 2 patient proof-of-concept trial in the second half of 2026."

New P2 trial • Trial status • Atopic Dermatitis